Journal of Pharmacological Sciences is a leading peer-reviewed academic journal dedicated to the field of pharmacology, published by the Japanese Pharmacological Society. Since its inception, this journal has offered an essential platform for the dissemination of high-quality research, contributing significantly to advancements in molecular medicine and pharmacology. With an impact factor that places it in the prestigious Q2 quartile for both categories, the journal has established itself as a credible source of innovative findings and methodologies since its transition to Open Access in 2015. This accessibility enables a broader audience, including researchers, healthcare professionals, and students, to engage with valuable insights and discussions pertinent to drug development, pharmacodynamics, and therapeutic strategies. Based in Kyoto, Japan, the journal serves as a vital resource for the global pharmacological community, encouraging collaboration and research that leads to improved health outcomes. For more information, submissions, and access to the latest research, visit the journal’s website.

COR ET VASA is a prominent peer-reviewed journal in the field of cardiology and cardiovascular medicine, published by the Czech Society of Cardiology and Czech Society of Cardiovascular Surgery. Established in 1961, and continuing its legacy from 2006 to 2024, this journal serves as an essential platform for disseminating significant research findings, clinical studies, and innovative treatments in cardiovascular health. While currently positioned in the Q4 quartile, the journal aims to enhance its impact by fostering knowledge sharing among researchers, clinicians, and students alike. The journal, with its publication in Czech Republic, provides a unique perspective to the European cardiovascular community, allowing for invaluable insights and discourse. Researchers are encouraged to submit their manuscripts and contribute to the growing body of knowledge in this critical area, although it should be noted that COR ET VASA does not offer open access options at this time. As the field of cardiovascular medicine evolves, COR ET VASA remains committed to addressing the latest challenges and advancements, nurturing a rich dialogue within the community.

CARDIOVASCULAR DRUGS AND THERAPY, published by Springer, is a premier journal dedicated to the latest advances in cardiovascular pharmacology and therapeutics. With a significant impact factor and esteemed rankings in cardiology and pharmacology, this journal is positioned in the top quartile categories, reflecting its influence and contribution to the field. Since its inception in 1987, the journal has served an international audience, providing a platform for researchers and practitioners to publish high-quality original research, critical reviews, and innovative clinical studies that address pressing issues in cardiovascular health. The journal's rigorous peer-review process ensures the utmost scholarly merit, making it an essential resource for professionals aiming to stay at the forefront of cardiovascular drug research and therapy. While not an open-access publication, it is widely available through institutional subscriptions, enhancing its reach within the global community of cardiology researchers and practitioners. Located in the Netherlands, CARDIOVASCULAR DRUGS AND THERAPY continues to play a vital role in advancing our understanding of cardiovascular diseases and the pharmacological solutions available to combat them.

Acta Cardiologica Sinica is a distinguished journal dedicated to the advancement of cardiology and cardiovascular medicine, published by the Taiwan Society of Cardiology. Since its inception in 1988, this journal has provided a platform for researchers and clinicians to share cutting-edge findings and insights into cardiac health, cardiovascular diseases, and innovative treatment strategies. With an impressive Q3 classification in the Cardiology category for 2023, the journal is recognized for its contributions to the field, ranked #208 out of 387 in Scopus, placing it within the 46th percentile of medical journals. Although it currently does not offer open access options, it remains a valued resource for the global cardiovascular community. The journal's commitment to disseminating high-quality research papers, reviews, and case studies ensures that it plays a vital role in improving cardiovascular health practices and outcomes. For researchers, professionals, and students alike, Acta Cardiologica Sinica is essential reading for staying informed about the latest developments in cardiology.

Cardiovascular Therapeutics is a renowned Open Access journal, published by WILEY-HINDAWI, that has been at the forefront of advancing knowledge in the field of cardiology and cardiovascular medicine since its establishment. With a strong commitment to disseminating high-quality research, the journal has successfully positioned itself within the Q2 quartile in multiple categories, including Cardiology and Cardiovascular Medicine, Medicine (miscellaneous), and Pharmacology. The journal is indexed in Scopus, achieving impressive rankings, such as #95 out of 387 in Cardiology, and #87 out of 272 in Medical Pharmacology. Situated in the United Kingdom, Cardiovascular Therapeutics embraces an Open Access model since 2019, ensuring that groundbreaking research is accessible to researchers, practitioners, and students across the globe. The journal is dedicated to publishing original research articles, reviews, and clinical studies that contribute to the understanding and treatment of cardiovascular diseases, making it an essential resource for those invested in improving patient outcomes and advancing therapeutic strategies in this vital area of medicine.

Cardiovascular Innovations and Applications is a premier open-access journal dedicated to advancing knowledge in the field of cardiovascular medicine. Published by COMPUSCRIPT since 2016, this journal provides a platform for the dissemination of innovative research and applications that address crucial topics in cardiology, aiming to bridge the gap between clinical practice and cutting-edge research. With an ISSN of 2009-8618 and an E-ISSN of 2009-8782, it operates on a global scale, facilitating access to high-quality content without financial barriers. The journal is positioned within the Medicine - Cardiology and Cardiovascular Medicine category, and its current Scopus rank of #321/387 reflects its potential for growth and influence in the academic community, being in the 17th percentile. Researchers, healthcare professionals, and students will find Cardiovascular Innovations and Applications an invaluable resource in their quest for the latest findings and advancements in cardiovascular health and treatment methodologies.

American Journal of Cardiovascular Drugs, published by ADIS INT LTD, is a premier peer-reviewed journal dedicated to the field of cardiology and cardiovascular medicine. With an ISSN of 1175-3277 and an E-ISSN of 1179-187X, this esteemed journal has established itself as a crucial platform for disseminating high-quality research since its inception in 2001. It holds a significant position in its domain, ranking in the second quartile (Q2) across several categories including Cardiology, Medicine (miscellaneous), and Pharmacology (medical) for the year 2023. With its Scopus ranks placing it in the 81st percentile for Cardiology and 77th percentile for Pharmacology, the journal is highly regarded among professionals, researchers, and students alike. While it is not an open-access journal, its comprehensive articles and systematic reviews provide an in-depth exploration of cardiovascular drug therapy, therapeutic advancements, and clinical practices, making it an invaluable resource for anyone invested in the future of cardiovascular health.

Welcome to the Journal of Cardiovascular Medicine, a leading platform for the dissemination of high-quality research in the field of cardiology and cardiovascular medicine. Published by Lippincott Williams & Wilkins, this esteemed journal boasts an ISSN of 1558-2027 and an E-ISSN of 1558-2035, reflecting its commitment to accessible and innovative cardiovascular research. With a significant impact factor and ranked Q2 in both Cardiology and Cardiovascular Medicine as well as in Medicine (Miscellaneous) for 2023, the journal is recognized for its contributions to advancing knowledge and practice in this critical area of health. The journal disseminates original research, reviews, and clinical studies, aimed at clinicians, researchers, and healthcare professionals who are dedicated to improving cardiovascular health outcomes. With a continuous commitment to evolving research from 2006 to 2024, the journal is an essential resource for those looking to stay at the forefront of the latest discoveries and methodologies in cardiovascular medicine.

Future Cardiology, published by Future Medicine Ltd, is an esteemed journal dedicated to advancing the field of cardiology and cardiovascular medicine. With an ISSN of 1479-6678 and an E-ISSN of 1744-8298, this journal has been serving as a vital platform for researchers and healthcare professionals since its inception in 2006. The journal features rigorously peer-reviewed articles, offering insights into innovative treatments, clinical studies, and cutting-edge research developments. Although it is currently categorized as Q3 in Cardiology and Cardiovascular Medicine and Q4 in Molecular Medicine, its growing impact is evident in its dedicated audience and commitment to fostering dialogue in the cardiovascular community. Future Cardiology provides an invaluable opportunity for scholars to share their findings and enhance knowledge in this critical area of healthcare, a pursuit that is ever more important as cardiovascular diseases continue to be a leading health concern worldwide. Access options are through standard subscriptions, allowing in-depth exploration of articles that push the boundaries of cardiological science.

Journal of the Practice of Cardiovascular Sciences, published by Wolters Kluwer Medknow Publications, is an esteemed Open Access journal dedicated to advancing knowledge in the field of cardiovascular health. With its ISSN 2395-5414 and E-ISSN 2454-2830, the journal serves as a vital platform for researchers, healthcare professionals, and students to disseminate and access high-quality studies, innovations, and practical applications related to cardiovascular sciences. Established in 2015 as an Open Access journal, it promotes widespread sharing of insights to enhance cardiovascular practices and address contemporary challenges in the field. As part of a reputable publishing group, the journal is poised for growth and impact, contributing significantly to the ongoing dialogue in cardiovascular research and clinical practice.